Hang Su, Ph.D.

• Professional Background

  Education

  • 2008 - MS - Biochemistry and Molecular Biology - School of Life Sciences, Sun Yat-sen (Zhongshan) University,
  • 2003 - BS - Biotechnology - School of Life Sciences, Sun Yat-sen (Zhongshan) University,
  • Postdoctoral Training - Cancer Research - University of Texas Health Science Center

  Appointments

  • 2/2013 - Assistant Professor/Research - UTHSCSA, Radiation Oncology, San Antonio

• Instruction & Training

  • 1/2008 - Present, Jinan University, Guangzhou, China

• Publications

  Journal Article

  Ha CS, Michalek JE, Elledge R, Kelley KR, Ganapathy S, Su H, Jenkins CA, Agiris A, Swords R, Eng TY, Karnad A, Crownover RL, Swanson GP, Goros M, Pollock BH, Yuan Z. p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study Molecular Oncology 2016 Jan;10(1):148-56. Long M, Wu J, Hao J, Liu W, Tang Y, Li X, Su H, Qiu W. Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation In Vitro Cell Dev Biol Anim 2015 Nov;51(10):1077-1084. Su H, Ganapathy S, Li X, Yuan Z, Ha C. p53-Based Strategy for Protection of Bone Marrow from Y-90 Ibritumomab Tiuxetan Int J Radiat Oncol Biol Phys 2015 Aug;92(5):1116-1122. Elledge RM, Yuan B, Cheng L, Chiang HC, Xu X, Han Y, Su H, Wang L, Zhang B, Lin J, LI X, Xie X, Wang T, Tekmal RR, Curiel TJ, Yuan ZM, HU Y, Ye Q, Li R. A phosphotyrosine switch determines the antitumor activity of ERβ J Clin Invest 2014 Aug;124(8):3378-3390.